
|Videos|May 1, 2013
Patrick Gleason of Prime Therapeutics on Pharmacogenomic Testing
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Advertisement
Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Implementing Enfortumab Vedotin-ejfv Plus Pembrolizumab: Navigating Safety Data and the Pharmacist’s Role
2
Daratumumab Boosts Depth and Durability of Response After ASCT, Offering Clear Guidance for Pharmacist Counseling
3
ACIP Votes to End Universal Hepatitis B Vaccination Recommendation for Infants
4
American Cancer Society Updates Cervical Cancer Screening Guidelines to Include Self-Collection for HPV Testing
5

















































































































































































































